How come that biosimilar medicines are still heavily debated today?

Smart reform of EU pharma and IP legislation key to boosting… 28 June 2022 Generic and biosimilar medicines lower healthcare treatment costs dramatically and…
EMA/HMA share definitive EU-wide position on biosimilar… 19 September 2022 The Biosimilar medicines group, a Medicines for Europe sector group,…
European patients need improved access to biosimilar… 22 April 2021 Fifteen years after the first global approval, biosimilar medicines systemically…
The Supplementary Protection Certificate (SPC) manufacturing… 1 July 2022 Today the transitional period for the application of the Supplementary…